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Background: The use of glycoprotein (Gp) IIb/IIIa receptor inhibitor in primary percutaneous coronary intervention (PCI) has been known to 
improve the clinical outcomes in patients with ST-elevation myocardial infarction (STEMI). But, there were little data for the upstream use of Gp 
IIb/IIIa receptor inhibitor with adequate clopidogrel loading. Therefore, this study tried to investigate whether upstream use of Gp IIb/IIIa receptor 
inhibitor (Clotinab, ISU ABXIS, Seoul) had the beneficial role for clinical outcomes and tissue-level perfusion in the setting of 600 mg clopidogrel 
loading in patients with STEMI.
Methods: A total 761 patients among 914 patients with STEMI within 12 hours from symptom onset were randomized to upstream use with 
Clotinab at emergency room [group 1: n=378] or only bail out use according to operater’s discretion during PCI [group 2: n=383]. All patients were 
prescribed a clopidogrel 600-mg before primary PCI. The primary end-point of this study was a 30-day incidence of MACE including death, non-fatal 
MI, target vessel revascularization and stroke.
Results: Grade Thrombolysis in Myocardial Infarction (TIMI) 0 was siginifcantly higher in group 2 before PCI (50.0 % vs. 58.2 %, p=0.02). Gp IIb/
IIIa receptor inhibitor in group 2 was used in 196 patients (51.2 %). The MACEs occurred in 32 patients (8.5 %) in group 1 and 36 patients (9.4 
%) in group 2, which was not significantly different (p=0.65). But, the incidence of major and minor bleeding was significantly higher in group 1 [20 
(5.3 %) vs. 5 (1.3 %), p =0.002]. Secondary end-points including corrected TIMI frame count (cTFC), myocardial blush grade (MBG) and ST-segment 
resolution (STR) at 90 minutes were no significantly different between 2 groups.
Conclusions: The upstream use of Gp IIb/IIa receptor inhibitor with the 600 mg clopidogrel loading was not associated with both reduction of the 
MACEs and improvement of coronary perfusion after primary PCI in STEMI compared to use as necessary.
